Open access
Aug 2026
Proteinuria as the cause of early dose modification in Japanese patients with metastatic colorectal cancer treated with fruquintinib: a multicenter real-world study.
Fruquintinib demonstrated feasible effectiveness and manageable toxicity in Japanese patients with mCRC and proteinuria was a major determinant of treatment feasibility and frequently led to early dose modification.
Shohei Udagawa, Chihiro Ishizuka, H. Osumi et al.
· International Journal of Cli... · 0 citations